What’s New

Bristol-Myers Squibb’s Opdivo ® (nivolumab) + Low- Dose Yervoy ® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and Irinotecan

Read the press release


EVENTS

Michael’s Mission 8th Annual Benefit
An Evening Honoring
Donna M. Introcaso-Allison, Founder and CEO IntroInc.
2017 LEADERSHIP AWARD
In Memory of Kristen R. McRedmond-Hope Award Patient Advocacy
& Joseph Orlando-Hope Award Patient Mentorship
Karen Walsh-Hope Award Patient Outreach & Awareness
8th Annual Gala E-Journal

View All Events